Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma. Data of 338 Chinese patients from the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib study data...
Saved in:
| Main Authors: | Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Christina SM Yip, Xiaolei Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317695030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01) -
Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
by: Yaohong Wen, et al.
Published: (2025-04-01) -
Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis
by: Xu Li, et al.
Published: (2024-09-01) -
Concurrent Radiation and Immunotherapy for Unresectable Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombus
by: Nithya Krishnamurthy, BA, et al.
Published: (2025-10-01) -
Sorafenib-treated hepatocellular carcinoma with or without prior direct-acting antiviral therapy for hepatitis C: outcomes and survival
by: Rania Lithy, et al.
Published: (2025-08-01)